MEI Pharma reports clinical data on oral CDK9 inhibitor voruciclib at ASH2023; safety profile well-tolerated

Lite Strategy, Inc.

Voruciclib monotherapy up to 200 mg on intermittent schedule well-tolerated; no DLTs. Common AEs: diarrhea, nausea, anemia, fatigue.
On-target Mcl-1 and RNA Pol II p-S2 reductions demonstrated in correlative pharmacodynamic studies.
In AML monotherapy: 1 patient achieved morphologic leukemia-free state; 9 had stable disease (2 for ≥3 months).
In B-cell malignancies: 4 patients had stable disease with tumor size decrease.
Combination with venetoclax ongoing; no DLTs or overlapping toxicity; anti-tumor activity observed with multiple patients on therapy ≥4 months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.